stockrow
Friday 6 November 2026
Export APRE’s income statement to Excel — free account
Aprea Therapeutics, Inc.
APRE Healthcare Biotechnology
Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024.
- Revenue
- −98.4%
- EPS
- +80.9%
- Free cash flow
- −5.22%
Quarter to September 2026, against a year earlier
0.52
0.02
+4.00%
Follow APRE
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (62.83%) | (47.44%) | (41.85%) | (79.37%) |
+8 more TTM periods Free account |
|
| (53.24%) | (41.30%) | (35.25%) | (63.14%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(40.97%) | (31.65%) | (28.46%) | (98.00%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(0.24) | (0.23) | (0.82) | (1.97) | |
Free Cash Flow |
(12.74) | (12.19) | (12.02) | (12.89) | |
Capital Expenditures |
(0.02) | (0.02) | — | — | |
| Other line items | |||||
Cash ROIC |
(17.70%) | (15.30%) | (13.65%) | (47.68%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,465.17% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,266.92% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 167.34% | |
Operating CF/Net income |
0.90 | 0.99 | 1.01 | 1.02 | |
Depreciation/Fixed assets |
0.36 | 0.34 | 0.40 | 0.36 | |
Capex/Depreciation |
(0.68) | (1.04) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.04 | |
Operating CF per Share |
(0.24) | (0.23) | (0.82) | (1.97) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026